Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17130901 | AQUEOUS SYSTEMS AND METHODS OF TREATING AQUEOUS SYSTEMS WITH TREATMENT AGENTS OR INHIBITING OR PREENTING GROWTH THEREIN | December 2020 | November 2023 | Abandon | 35 | 2 | 0 | No | No |
| 17247779 | QUATERNARY DISINFECTANT COMPOSITION WITH ANIONIC SCALE INHIBITING AGENT | December 2020 | August 2023 | Allow | 32 | 2 | 0 | No | No |
| 17129666 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | December 2020 | March 2024 | Allow | 39 | 3 | 0 | No | Yes |
| 17119305 | NEAR INFRARED FLUORESCENT DYES, FORMULATIONS AND RELATED METHODS | December 2020 | March 2023 | Allow | 27 | 1 | 0 | No | No |
| 17111371 | Spherical rHDLs For Targeted Imaging | December 2020 | March 2024 | Allow | 39 | 3 | 0 | No | No |
| 17059334 | HALOGENATED BIOTIN-MODIFIED DIMER AND USE THEREOF | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17096738 | CCR5 and CD4 siRNA-Targeted Phospholipid Nanosomes Therapeutics for Treatment of HIV-1 and Other Diseases | November 2020 | January 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17053042 | OXAZINE COMPOUND AND APPLICATION THEREOF | November 2020 | February 2023 | Allow | 27 | 2 | 0 | No | No |
| 17085861 | LHRH-CONJUGATED PRODIGIOSIN AND USES THEREOF | October 2020 | July 2024 | Abandon | 44 | 4 | 1 | Yes | No |
| 17051985 | VISUALIZING AGENT FOR VISUALIZING HYALURONAN | October 2020 | July 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17085957 | LHRH-PACLITAXEL CONJUGATES AND METHODS OF USE | October 2020 | June 2024 | Abandon | 43 | 4 | 1 | Yes | No |
| 17083465 | GAS SENSOR NANOCOMPOSITE MEMBRANES | October 2020 | February 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17050200 | EDIBLE PLANT EXOSOME-LIKE NANOVECTORS FOR VACCINATION | October 2020 | September 2022 | Abandon | 23 | 1 | 0 | No | No |
| 17079375 | FLUORESCEIN AND BENOXINATE COMPOSITIONS | October 2020 | April 2022 | Allow | 18 | 0 | 0 | No | No |
| 17072243 | DICARBOXYLIC ACID FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF | October 2020 | April 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17046639 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | October 2020 | March 2023 | Allow | 29 | 2 | 0 | No | No |
| 17063848 | METHODS AND COMPOSITIONS FOR INCREASING RED BLOOD CELLS | October 2020 | June 2023 | Allow | 33 | 2 | 0 | No | No |
| 17035490 | SUBLINGUAL AND BUCCAL ADMINISTRATIONS OF FLUORESCENT AGENTS FOR OPTICAL IMAGING | September 2020 | August 2024 | Abandon | 46 | 5 | 0 | Yes | No |
| 16978820 | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CANCER USING NANOPARTICLES OF TAXANES | September 2020 | July 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16978476 | ANTHRACYCLINE ENCAPSULATED WITH A POLYSACCHARIDE FOR USE IN THE TREATMENT OF TUMOURS | September 2020 | May 2023 | Abandon | 32 | 2 | 0 | No | No |
| 16976909 | NANOPARTICLE COMPOSITIONS | August 2020 | July 2022 | Abandon | 23 | 1 | 0 | No | No |
| 17006785 | Nano coordination polymer and preparation method and application thereof | August 2020 | July 2023 | Abandon | 35 | 2 | 0 | No | No |
| 16992385 | REDUCED AND OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF | August 2020 | May 2023 | Allow | 33 | 3 | 1 | Yes | No |
| 16969850 | PATCHES COMPRISING URUSHIOL, TEST PANELS COMPRISING THE SAME, AND METHODS OF USING THE SAME | August 2020 | January 2023 | Allow | 29 | 3 | 0 | Yes | No |
| 16968666 | METHOD AND COMPOSITION FOR THE DETECTION OF ARTHROPODS | August 2020 | March 2023 | Abandon | 31 | 4 | 0 | No | No |
| 16989088 | Antioxidant, Antibacterial, Injectable Lignin-Gelatin Composite Cryogels for Wound Healing and Tissue Engineering | August 2020 | November 2020 | Allow | 3 | 0 | 0 | No | No |
| 16967213 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | August 2020 | March 2024 | Allow | 44 | 4 | 0 | No | No |
| 16967303 | ALPHA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | August 2020 | March 2023 | Allow | 31 | 2 | 0 | No | No |
| 16964919 | NANOMETRIC PHARMACEUTICAL COMPOSITION IN THE FORM OF LIPOSOMES OR NANOEMULSION CONTAINING SPECIFIC SEQUENCES OF INTERFERENCE RNA | July 2020 | March 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 16932229 | SOLID DRUG TABLETS FOR IMPLANTABLE DRUG DELIVERY DEVICES | July 2020 | March 2021 | Allow | 7 | 1 | 0 | No | No |
| 16946998 | SODIUM CHLORIDE SOLUTION FOR DRUG RECONSTITUTION OR DILUTION | July 2020 | September 2022 | Abandon | 26 | 4 | 0 | Yes | Yes |
| 16927777 | HYPERTONIC PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-PLATINUM CHEMOPROTECTANT AGENT | July 2020 | May 2021 | Allow | 10 | 1 | 0 | Yes | No |
| 16961899 | A Novel Blank Liposome with Ginsenoside Rg3 or its Analog as Membrane Materials and Preparations and Uses Thereof | July 2020 | August 2023 | Allow | 37 | 2 | 0 | No | No |
| 16913567 | SPINOSYN FORMULATIONS FOR TREATMENT OF DEMODEX-INDUCED OCULAR AND FACIAL CONDITIONS | June 2020 | October 2021 | Allow | 15 | 0 | 0 | Yes | No |
| 16958636 | METHOD OF TREATMENT FOR SOLID TUMORS CONTAINING HYPOXIA AND/OR STROMA FEATURES | June 2020 | March 2024 | Allow | 45 | 3 | 1 | No | No |
| 16911831 | SURFACE GRADIENT CROSS-LINKING METHOD OF ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE AND THE APPLICATION THEREOF | June 2020 | January 2024 | Allow | 42 | 2 | 1 | No | No |
| 16957017 | TRANSDERMAL NON-AQUEOUS NANOEMULGELS FOR SYSTEMIC DELIVERY OF AROMATASE INHIBITOR | June 2020 | August 2021 | Allow | 14 | 1 | 0 | No | No |
| 16636735 | PROCESS FOR THE PREPARATION OF A SUSPENSION OF NANOSIZED SYNTHETIC ZEOLITE MATERIALS, SUSPENSIONS OF NANOSIZED SYNTHETIC ZEOLITE MATERIALS OBTAINED BY SAID PROCESS AND THEIR USES IN THERAPY AND DIAGNOSIS | June 2020 | May 2022 | Allow | 27 | 2 | 0 | No | No |
| 16955096 | NANOPARTICLES FOR USE IN ENHANCING BRAIN PERFORMANCES OR IN TREATING STRESS | June 2020 | June 2022 | Allow | 24 | 2 | 0 | No | No |
| 16955092 | NANOPARTICLES FOR USE FOR TREATING A NEURONAL DISORDER | June 2020 | July 2022 | Allow | 25 | 1 | 0 | No | No |
| 16903920 | REINFORCED TISSUE GRAFT | June 2020 | December 2023 | Allow | 42 | 3 | 0 | No | No |
| 16898804 | Compositions Comprising Milk Fat Globules and Methods of Making Same | June 2020 | January 2022 | Allow | 19 | 5 | 0 | Yes | No |
| 16894287 | DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES | June 2020 | July 2021 | Allow | 13 | 1 | 0 | No | No |
| 16880065 | Cationic Mucic Acid Polymer-Based Delivery Systems | May 2020 | February 2021 | Allow | 8 | 1 | 0 | No | No |
| 16766009 | METHODS FOR TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES | May 2020 | July 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16877805 | SCAFFOLDS FOR CELL COLLECTION OR ELIMINATION | May 2020 | March 2023 | Abandon | 34 | 2 | 0 | No | Yes |
| 16861128 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | April 2020 | January 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 16758792 | NANOPARTICLE CANCER THERAPY | April 2020 | March 2023 | Abandon | 35 | 3 | 0 | Yes | Yes |
| 16758770 | SINGLE- AND MIXED-METAL NANOPARTICLES, NANOPARTICLE CONJUGATES, DEVICES FOR MAKING NANOPARTICLES, AND RELATED METHODS OF USE | April 2020 | June 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16851986 | MODIFIED-RNA NANOPARTICLES FOR INDUCTION OF RNA INTERFERENCE | April 2020 | September 2022 | Allow | 29 | 2 | 0 | Yes | No |
| 16756767 | AN ANTI-CANCER AGENT COMPRISING A TUMOUR HOMING PEPTIDE HAVING ARSENIC BONDED TO CYSTEINE RESIDUES | April 2020 | July 2023 | Allow | 39 | 4 | 0 | No | No |
| 16847883 | Electrochemical Sensor System | April 2020 | February 2021 | Allow | 10 | 1 | 0 | No | No |
| 16847272 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | April 2020 | July 2022 | Allow | 27 | 3 | 0 | No | No |
| 16837232 | Solid Substrates for Promoting Cell and Tissue Growth | April 2020 | June 2021 | Allow | 14 | 1 | 0 | No | No |
| 16650266 | COMPOSITIONS THAT TARGET TUMOR-ASSOCIATED MACROPHAGES AND METHODS OF USE THEREFOR | March 2020 | September 2022 | Allow | 30 | 1 | 0 | No | No |
| 16826475 | Injection Molded Medical Devices Made From A High Molecular Weight Polyethylene | March 2020 | May 2023 | Allow | 38 | 5 | 0 | No | Yes |
| 16820593 | FLUORESCEIN AND BENOXINATE COMPOSITIONS | March 2020 | July 2020 | Allow | 4 | 0 | 0 | No | No |
| 16647225 | INJECTABLE HYBRID ALGINATE HYDROGELS AND USES THEREOF | March 2020 | May 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16645288 | Invention Relating to Nanoparticles Containing Taxanes for Administration by Inhalation | March 2020 | November 2022 | Abandon | 32 | 2 | 0 | No | No |
| 16810548 | LIGHT-MEDIATED TREATMENTS OF METASTATIC CANCERS | March 2020 | December 2022 | Abandon | 34 | 2 | 0 | No | No |
| 16644482 | SONODYNAMIC THERAPY USING MICROBUBBLES AND PULSED WAVE ULTRASOUND METHODS AND SYSTEMS | March 2020 | June 2023 | Allow | 40 | 2 | 0 | No | No |
| 16798992 | VISIBLE LIGHT-ACTIVATED DYES AND METHODS OF USE THEREOF | February 2020 | October 2023 | Allow | 43 | 3 | 0 | No | No |
| 16799248 | SETTABLE SILICON NITRIDE CEMENTS | February 2020 | July 2023 | Abandon | 41 | 2 | 0 | No | No |
| 16641606 | TOPICAL SILK COMPOSITIONS AND METHODS OF USING | February 2020 | November 2021 | Allow | 21 | 1 | 0 | Yes | No |
| 16796476 | METHOD FOR TREATING A SWALLOWING DISORDER | February 2020 | June 2020 | Allow | 4 | 1 | 0 | No | No |
| 16640539 | FBSA-BASED THERAPEUTIC AND RADIOIMAGING CONJUGATES TARGETING CARBONIC ANHYDRASE POSITIVE CANCERS | February 2020 | September 2022 | Allow | 31 | 2 | 0 | No | No |
| 16640620 | CONFORMATIONAL RESTRICTION OF CYANINE FLUOROPHORES IN FAR-RED AND NEAR-IR RANGE | February 2020 | December 2020 | Allow | 10 | 0 | 1 | No | No |
| 16795000 | COMPOSITIONS OF HYPOCHLOROUS ACID AND METHODS OF MANUFACTURE THEREOF | February 2020 | June 2022 | Allow | 28 | 2 | 0 | No | No |
| 16787589 | METHODS OF TREATING ADVANCED PROSTATE CANCER | February 2020 | August 2022 | Allow | 30 | 6 | 0 | Yes | Yes |
| 16786312 | INJECTABLE POROUS HYDROGELS | February 2020 | January 2024 | Allow | 47 | 3 | 0 | Yes | No |
| 16784202 | PRODRUG AND PROFLUORESCENT COMPOUNDS FOR SELECTIVE MITOCHONDRIAL IMAGING AND THERAPEUTIC TARGETING | February 2020 | August 2021 | Allow | 18 | 1 | 0 | No | No |
| 16635677 | DEGRADATION PREVENTING MEANS FOR IMMUNOASSAY REAGENT CONTAINING INSOLUBLE CARRIER PARTICLES | January 2020 | February 2023 | Allow | 37 | 1 | 0 | No | No |
| 16634644 | USE OF MIR-21 IN PREPARATION OF DRUG FOR TREATING INTRAUTERINE ADHESION AND/OR THIN ENDOMETRIUM | January 2020 | June 2022 | Allow | 28 | 1 | 0 | No | No |
| 16773911 | DEVICE AND METHOD FOR PROMOTING RAPID STRUT COVERAGE AND VASCULAR ENDOTHELIAL COVERAGE | January 2020 | October 2023 | Abandon | 44 | 2 | 0 | No | No |
| 16633744 | METHODS FOR REDUCING ELEVATED GLUCOSE LEVELS | January 2020 | January 2024 | Allow | 47 | 2 | 0 | No | Yes |
| 16632649 | PYROPHEOPHORBIDE CONJUGATE AND USE THEREOF IN THE TREATMENT OF CANCER AND AS A FLUORESCENT MARKER | January 2020 | January 2024 | Allow | 48 | 1 | 0 | No | No |
| 16630786 | PHARMACEUTICAL COMPOSITIONS OF SULFUR COLLOID AND PROCESSES THEREOF | January 2020 | July 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16630806 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | January 2020 | September 2022 | Allow | 32 | 2 | 0 | No | No |
| 16630676 | LONG-ACTING FORMULATIONS | January 2020 | June 2021 | Allow | 17 | 0 | 0 | No | No |
| 16732567 | HYBRIDOSOMES, COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THEIR PRODUCTION AND USES THEREOF | January 2020 | June 2022 | Allow | 29 | 3 | 0 | No | No |
| 16625899 | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONSIVE BIOPOLYMER NETWORKS | December 2019 | January 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16723563 | SODIUM CHLORIDE SOLUTION FOR DRUG RECONSTITUTION OR DILUTION | December 2019 | December 2021 | Abandon | 24 | 2 | 0 | No | No |
| 16625368 | HSP90 TARGETED CONJUGATES AND PARTICLE FORMULATIONS THEREOF | December 2019 | January 2023 | Abandon | 37 | 2 | 0 | No | Yes |
| 16721302 | Multisomes: Encapsulated Droplet Networks | December 2019 | March 2022 | Allow | 27 | 2 | 0 | No | No |
| 16720299 | MODIFIED-DEXTRANS FOR USE IN OPTICAL GLUCOSE ASSAYS | December 2019 | August 2020 | Allow | 8 | 1 | 0 | No | No |
| 16623740 | AN OSTEOADSORPTIVE FLUOROGENIC SUBSTRATE OF CATHEPSIN K FOR IMAGING OSTEOCLAST ACTIVITY AND MIGRATION | December 2019 | August 2021 | Allow | 20 | 0 | 0 | Yes | No |
| 16715972 | Composition for Transdermal Delivery of Cationic Active Agents | December 2019 | September 2020 | Allow | 9 | 1 | 0 | No | No |
| 16714182 | MULTIMODAL SILICA-BASED NANOPARTICLES | December 2019 | May 2022 | Allow | 29 | 2 | 0 | No | No |
| 16714516 | Viral Vector Production System | December 2019 | April 2024 | Allow | 52 | 1 | 0 | No | No |
| 16712215 | Methods And Compositions For Targeted Imaging | December 2019 | October 2020 | Allow | 10 | 0 | 0 | No | No |
| 16622136 | NON-VIRAL GENE DELIVERY AGENT COMPRISING LIPOPEPTIDE (LP) COMPOUNDS | December 2019 | April 2022 | Allow | 28 | 2 | 0 | No | No |
| 16711150 | SHAPE-PRESERVING POLYMERIC REPLICATION OF BIOLOGICAL MATTER | December 2019 | January 2021 | Allow | 13 | 3 | 0 | No | No |
| 16708302 | SYSTEM AND APPARATUS FOR POROUSLY-ENCAPSULATED MAGNETIC-NANOPARTICLE BIOSENSORS | December 2019 | October 2021 | Allow | 22 | 1 | 0 | Yes | No |
| 16706009 | DRUG DELIVERY SYSTEMS AND METHODS FOR TREATMENT OF BLADDER DYSFUNCTION OR DISORDER USING TROSPIUM | December 2019 | September 2023 | Allow | 45 | 4 | 0 | Yes | No |
| 16692744 | NANOSTRUCTURED SURFACES | November 2019 | September 2022 | Allow | 34 | 4 | 1 | Yes | No |
| 16614055 | LUMINESCENT PARTICLES BASED ON RARE EARTH ELEMENTS AND USE THEREOF AS A DIAGNOSTIC AGENT | November 2019 | June 2022 | Allow | 31 | 1 | 0 | Yes | No |
| 16613050 | COMBINATION OF AN APPLICATOR AND OF A SUSPENSION HAVING AN ACTIVE PRINCIPLE | November 2019 | November 2022 | Allow | 36 | 1 | 0 | No | No |
| 16612038 | QUINIC ACID-MODIFIED NANOPARTICLES AND USES THEREOF | November 2019 | June 2021 | Allow | 19 | 1 | 0 | No | No |
| 16672395 | COMPOSITIONS AND METHODS FOR TREATING TRANSIENT BIOFILMS | November 2019 | May 2022 | Allow | 31 | 2 | 1 | No | No |
| 16672393 | COMPOSITIONS AND METHODS FOR TREATING BIOFILMS WITHOUT INDUCING ANTIMICROBIAL RESISTANCE | November 2019 | June 2022 | Allow | 32 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CABRAL, ROBERT S.
With a 32.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CABRAL, ROBERT S works in Art Unit 1618 and has examined 717 patent applications in our dataset. With an allowance rate of 57.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner CABRAL, ROBERT S's allowance rate of 57.0% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CABRAL, ROBERT S receive 2.75 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CABRAL, ROBERT S is 33 months. This places the examiner in the 45% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +38.2% benefit to allowance rate for applications examined by CABRAL, ROBERT S. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.5% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.7% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 69.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 60.8% of appeals filed. This is in the 38% percentile among all examiners. Of these withdrawals, 56.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 62.4% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 54% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.